Determination of Regulatory Review Period for Purposes of Patent Extension; KDR 401 and 403 PACEMAKERS

Samenvatting

The Food and Drug Administration (FDA) has determined the regulatory review period for KDR 401 and 403 PACEMAKERS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims those medical devices.